Optimal sequencing strategies in the treatment of EGFR mutation–positive non–small cell lung cancer: Clinical benefits and cost-effectiveness

PURPOSE: To summarize current understanding of the efficacy, role, and cost-effectiveness of the available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), and to evaluate sequencing strategies based on the available evidence. Summary. EGFR TKIs are the current standard of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirsh, Vera, Singh, Jaspal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472210/
https://www.ncbi.nlm.nih.gov/pubmed/32885829
http://dx.doi.org/10.1093/ajhp/zxaa197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472210/
https://www.ncbi.nlm.nih.gov/pubmed/32885829
http://dx.doi.org/10.1093/ajhp/zxaa197

Ejemplares similares